HALOZYME THERAPEUTICS INC (HALO) Fundamental Analysis & Valuation

NASDAQ:HALO • US40637H1095

Current stock price

64.49 USD
-0.91 (-1.39%)
At close:
64.49 USD
0 (0%)
After Hours:

This HALO fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

8

1. HALO Profitability Analysis

1.1 Basic Checks

  • In the past year HALO was profitable.
  • HALO had a positive operating cash flow in the past year.
  • In the past 5 years HALO has always been profitable.
  • In the past 5 years HALO always reported a positive cash flow from operatings.
HALO Yearly Net Income VS EBIT VS OCF VS FCFHALO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M 400M 600M 800M

1.2 Ratios

  • HALO's Return On Assets of 12.55% is amongst the best of the industry. HALO outperforms 94.39% of its industry peers.
  • HALO's Return On Equity of 649.18% is amongst the best of the industry. HALO outperforms 100.00% of its industry peers.
  • HALO's Return On Invested Capital of 25.65% is amongst the best of the industry. HALO outperforms 98.26% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for HALO is significantly below the industry average of 27.17%.
  • The 3 year average ROIC (20.76%) for HALO is below the current ROIC(25.65%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 12.55%
ROE 649.18%
ROIC 25.65%
ROA(3y)16.77%
ROA(5y)19.55%
ROE(3y)369.08%
ROE(5y)286.14%
ROIC(3y)20.76%
ROIC(5y)19.08%
HALO Yearly ROA, ROE, ROICHALO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200 400 600

1.3 Margins

  • The Profit Margin of HALO (22.69%) is better than 93.42% of its industry peers.
  • HALO's Profit Margin has declined in the last couple of years.
  • HALO's Operating Margin of 58.45% is amongst the best of the industry. HALO outperforms 100.00% of its industry peers.
  • HALO's Operating Margin has improved in the last couple of years.
  • HALO's Gross Margin of 83.62% is amongst the best of the industry. HALO outperforms 86.85% of its industry peers.
  • In the last couple of years the Gross Margin of HALO has remained more or less at the same level.
Industry RankSector Rank
OM 58.45%
PM (TTM) 22.69%
GM 83.62%
OM growth 3Y10.06%
OM growth 5Y1.62%
PM growth 3Y-9.5%
PM growth 5Y-14%
GM growth 3Y1.96%
GM growth 5Y-0.04%
HALO Yearly Profit, Operating, Gross MarginsHALO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. HALO Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so HALO is creating value.
  • Compared to 1 year ago, HALO has less shares outstanding
  • HALO has less shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, HALO has a worse debt to assets ratio.
HALO Yearly Shares OutstandingHALO Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M
HALO Yearly Total Debt VS Total AssetsHALO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B 2B 2.5B

2.2 Solvency

  • HALO has an Altman-Z score of 3.80. This indicates that HALO is financially healthy and has little risk of bankruptcy at the moment.
  • HALO's Altman-Z score of 3.80 is fine compared to the rest of the industry. HALO outperforms 70.02% of its industry peers.
  • HALO has a debt to FCF ratio of 6.00. This is a slightly negative value and a sign of low solvency as HALO would need 6.00 years to pay back of all of its debts.
  • Looking at the Debt to FCF ratio, with a value of 6.00, HALO belongs to the top of the industry, outperforming 90.72% of the companies in the same industry.
  • A Debt/Equity ratio of 43.89 is on the high side and indicates that HALO has dependencies on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 43.89, HALO is doing worse than 83.17% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 43.89
Debt/FCF 6
Altman-Z 3.8
ROIC/WACC3.12
WACC8.21%
HALO Yearly LT Debt VS Equity VS FCFHALO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500M 1B 1.5B 2B

2.3 Liquidity

  • A Current Ratio of 4.66 indicates that HALO has no problem at all paying its short term obligations.
  • With a Current ratio value of 4.66, HALO perfoms like the industry average, outperforming 53.00% of the companies in the same industry.
  • A Quick Ratio of 3.66 indicates that HALO has no problem at all paying its short term obligations.
  • The Quick ratio of HALO (3.66) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 4.66
Quick Ratio 3.66
HALO Yearly Current Assets VS Current LiabilitesHALO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. HALO Growth Analysis

3.1 Past

  • The earnings per share for HALO have decreased by -2.36% in the last year.
  • Measured over the past years, HALO shows a very strong growth in Earnings Per Share. The EPS has been growing by 35.63% on average per year.
  • HALO shows a strong growth in Revenue. In the last year, the Revenue has grown by 37.55%.
  • Measured over the past years, HALO shows a very strong growth in Revenue. The Revenue has been growing by 39.16% on average per year.
EPS 1Y (TTM)-2.36%
EPS 3Y22.99%
EPS 5Y35.63%
EPS Q2Q%-119.05%
Revenue 1Y (TTM)37.55%
Revenue growth 3Y28.38%
Revenue growth 5Y39.16%
Sales Q2Q%51.6%

3.2 Future

  • Based on estimates for the next years, HALO will show a quite strong growth in Earnings Per Share. The EPS will grow by 16.27% on average per year.
  • The Revenue is expected to grow by 5.11% on average over the next years.
EPS Next Y97.97%
EPS Next 2Y55.95%
EPS Next 3Y36.66%
EPS Next 5Y16.27%
Revenue Next Year26.75%
Revenue Next 2Y19.57%
Revenue Next 3Y15.64%
Revenue Next 5Y5.11%

3.3 Evolution

  • Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
HALO Yearly Revenue VS EstimatesHALO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 500M 1B 1.5B 2B
HALO Yearly EPS VS EstimatesHALO Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 2 4 6 8 10

More info and screens

Find the best growth stocksShow best growing peers

9

4. HALO Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 15.62, which indicates a correct valuation of HALO.
  • 95.16% of the companies in the same industry are more expensive than HALO, based on the Price/Earnings ratio.
  • Compared to an average S&P500 Price/Earnings ratio of 25.60, HALO is valued a bit cheaper.
  • A Price/Forward Earnings ratio of 7.89 indicates a rather cheap valuation of HALO.
  • Based on the Price/Forward Earnings ratio, HALO is valued cheaply inside the industry as 98.26% of the companies are valued more expensively.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 22.84, HALO is valued rather cheaply.
Industry RankSector Rank
PE 15.62
Fwd PE 7.89
HALO Price Earnings VS Forward Price EarningsHALO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, HALO is valued cheaply inside the industry as 95.94% of the companies are valued more expensively.
  • Based on the Price/Free Cash Flow ratio, HALO is valued cheaply inside the industry as 95.16% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 21.33
EV/EBITDA 10.62
HALO Per share dataHALO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10 -10

4.3 Compensation for Growth

  • HALO's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • HALO has an outstanding profitability rating, which may justify a higher PE ratio.
  • HALO's earnings are expected to grow with 36.66% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.16
PEG (5Y)0.44
EPS Next 2Y55.95%
EPS Next 3Y36.66%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. HALO Dividend Analysis

5.1 Amount

  • HALO does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

HALO Fundamentals: All Metrics, Ratios and Statistics

HALOZYME THERAPEUTICS INC

NASDAQ:HALO (4/2/2026, 8:00:01 PM)

After market: 64.49 0 (0%)

64.49

-0.91 (-1.39%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-17
Earnings (Next)05-04
Inst Owners107.69%
Inst Owner Change-19.78%
Ins Owners0.87%
Ins Owner Change0.83%
Market Cap7.61B
Revenue(TTM)1.40B
Net Income(TTM)316.89M
Analysts76
Price Target86.19 (33.65%)
Short Float %11.76%
Short Ratio7.57
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-53.57%
Min EPS beat(2)-110.7%
Max EPS beat(2)3.56%
EPS beat(4)3
Avg EPS beat(4)-18.27%
Min EPS beat(4)-110.7%
Max EPS beat(4)19.26%
EPS beat(8)7
Avg EPS beat(8)-1.32%
EPS beat(12)9
Avg EPS beat(12)0.23%
EPS beat(16)12
Avg EPS beat(16)2.67%
Revenue beat(2)2
Avg Revenue beat(2)1.65%
Min Revenue beat(2)1.13%
Max Revenue beat(2)2.18%
Revenue beat(4)4
Avg Revenue beat(4)6.95%
Min Revenue beat(4)1.13%
Max Revenue beat(4)12.81%
Revenue beat(8)7
Avg Revenue beat(8)6.15%
Revenue beat(12)8
Avg Revenue beat(12)3.65%
Revenue beat(16)10
Avg Revenue beat(16)2.56%
PT rev (1m)0%
PT rev (3m)11.18%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-15.58%
EPS NY rev (1m)-1.88%
EPS NY rev (3m)-1.4%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-3.6%
Revenue NY rev (1m)-0.11%
Revenue NY rev (3m)4.8%
Valuation
Industry RankSector Rank
PE 15.62
Fwd PE 7.89
P/S 5.45
P/FCF 21.33
P/OCF 11.68
P/B 155.92
P/tB N/A
EV/EBITDA 10.62
EPS(TTM)4.13
EY6.4%
EPS(NY)8.18
Fwd EY12.68%
FCF(TTM)3.02
FCFY4.69%
OCF(TTM)5.52
OCFY8.56%
SpS11.83
BVpS0.41
TBVpS-12.82
PEG (NY)0.16
PEG (5Y)0.44
Graham Number6.2
Profitability
Industry RankSector Rank
ROA 12.55%
ROE 649.18%
ROCE 34.76%
ROIC 25.65%
ROICexc 27.31%
ROICexgc 93.59%
OM 58.45%
PM (TTM) 22.69%
GM 83.62%
FCFM 25.55%
ROA(3y)16.77%
ROA(5y)19.55%
ROE(3y)369.08%
ROE(5y)286.14%
ROIC(3y)20.76%
ROIC(5y)19.08%
ROICexc(3y)25.83%
ROICexc(5y)35.19%
ROICexgc(3y)78.99%
ROICexgc(5y)74.81%
ROCE(3y)28.13%
ROCE(5y)25.85%
ROICexgc growth 3Y19.79%
ROICexgc growth 5YN/A
ROICexc growth 3Y19.91%
ROICexc growth 5YN/A
OM growth 3Y10.06%
OM growth 5Y1.62%
PM growth 3Y-9.5%
PM growth 5Y-14%
GM growth 3Y1.96%
GM growth 5Y-0.04%
F-Score5
Asset Turnover0.55
Health
Industry RankSector Rank
Debt/Equity 43.89
Debt/FCF 6
Debt/EBITDA 2.37
Cap/Depr 334.74%
Cap/Sales 21.1%
Interest Coverage 71.42
Cash Conversion 72.05%
Profit Quality 112.6%
Current Ratio 4.66
Quick Ratio 3.66
Altman-Z 3.8
F-Score5
WACC8.21%
ROIC/WACC3.12
Cap/Depr(3y)121.97%
Cap/Depr(5y)85.12%
Cap/Sales(3y)8%
Cap/Sales(5y)5.01%
Profit Quality(3y)116.88%
Profit Quality(5y)108.21%
High Growth Momentum
Growth
EPS 1Y (TTM)-2.36%
EPS 3Y22.99%
EPS 5Y35.63%
EPS Q2Q%-119.05%
EPS Next Y97.97%
EPS Next 2Y55.95%
EPS Next 3Y36.66%
EPS Next 5Y16.27%
Revenue 1Y (TTM)37.55%
Revenue growth 3Y28.38%
Revenue growth 5Y39.16%
Sales Q2Q%51.6%
Revenue Next Year26.75%
Revenue Next 2Y19.57%
Revenue Next 3Y15.64%
Revenue Next 5Y5.11%
EBIT growth 1Y48.02%
EBIT growth 3Y41.29%
EBIT growth 5Y41.42%
EBIT Next Year38.41%
EBIT Next 3Y22.4%
EBIT Next 5Y8.86%
FCF growth 1Y-23.82%
FCF growth 3Y14.89%
FCF growth 5Y46.43%
OCF growth 1Y36.01%
OCF growth 3Y39.48%
OCF growth 5Y63.66%

HALOZYME THERAPEUTICS INC / HALO Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for HALOZYME THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 7 / 10 to HALO.


Can you provide the valuation status for HALOZYME THERAPEUTICS INC?

ChartMill assigns a valuation rating of 9 / 10 to HALOZYME THERAPEUTICS INC (HALO). This can be considered as Undervalued.


What is the profitability of HALO stock?

HALOZYME THERAPEUTICS INC (HALO) has a profitability rating of 8 / 10.


What is the valuation of HALOZYME THERAPEUTICS INC based on its PE and PB ratios?

The Price/Earnings (PE) ratio for HALOZYME THERAPEUTICS INC (HALO) is 15.62 and the Price/Book (PB) ratio is 155.92.


What is the expected EPS growth for HALOZYME THERAPEUTICS INC (HALO) stock?

The Earnings per Share (EPS) of HALOZYME THERAPEUTICS INC (HALO) is expected to grow by 97.97% in the next year.